Acusphere Reports Mixed Top-Line Phase III Results For Imagify
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm contends RAMP-2 pivotal trial results for its cardiac imaging agent will support an NDA filing in the fourth quarter.